INS and Cognitive impairment: A small phase II trial (n = 30, no cognitive impairment or MCI) has commenced that compares three different devices for delivering intranasal insulin at two doses (20 IU and 40 IU) to address the discrepancies seen in the SNIFF trial (URL accessed on 4 March 2022, www.alzforum.org/therapeutics/nasal-insulin).